FDA Approval Summary: Brentuximab Vedotin in First‐Line Treatment of Peripheral T‐Cell Lymphoma

In November 2018, the U.S. Food and Drug Administration (FDA) approved brentuximab vedotin (BV) for the treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma or other CD30‐expressing peripheral T‐cell lymphomas (PTCL), including angioimmunoblastic T‐cell lymph...

Descripción completa

Detalles Bibliográficos
Autores principales: Richardson, Nicholas C., Kasamon, Yvette L., Chen, Haiyan, de Claro, R. Angelo, Ye, Jingjing, Blumenthal, Gideon M., Farrell, Ann T., Pazdur, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Regulatory Issues: FDA
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6516120/
https://www.ncbi.nlm.nih.gov/pubmed/30914464
http://dx.doi.org/10.1634/theoncologist.2019-0098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6516120/
https://www.ncbi.nlm.nih.gov/pubmed/30914464
http://dx.doi.org/10.1634/theoncologist.2019-0098

Ejemplares similares